Windward Bio’s IPO not only provides cash but also offers market validation for a TSLP-centered approach in severe asthma. The company’s lead program WIN378 targets an inflammatory protein in an ultra-long-acting injectable format, positioned to differentiate by dosing frequency compared with monthly standards. The prospectus-backed clinical update says mid-stage asthma results showed tolerability and measurable improvements in expiratory air expulsion and inflammation markers, including eosinophil reductions. Windward is moving WIN378 into Phase 3 with an expectation of next-year readouts. As immunology-driven respiratory programs mature, the capital raised here will likely pressure competitors to show similar biomarker-linked efficacy and regimen convenience while expanding development breadth into COPD and dermatology.